Media stories about BioCryst Pharmaceuticals (NASDAQ:BCRX) have trended somewhat negative recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of -0.03 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.3858127258992 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Global Marburgvirus Infection Market 2018 – Arno Therapeutics Inc, BioCryst Pharmaceuticals Inc, Eisai Co Ltd … (hightechcaller.com)
- Eye-Catching Hot Stock – BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) (stocksmarketcap.com)
- Fundamental & Quant Review of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX) and 22nd Century Group, Inc … (concordiareview.com)
- BioCryst Pharmaceuticals Partnering Research 2018 Along with Statistics, Forecasts (businessservices24.com)
- Noble Financial Reiterates “Buy” Rating for BioCryst Pharmaceuticals (BCRX) (americanbankingnews.com)
A number of analysts have recently commented on the company. BidaskClub raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Barclays assumed coverage on BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They issued an “equal weight” rating and a $6.00 price target for the company. ValuEngine cut BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 14th. Finally, Royal Bank of Canada raised BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. BioCryst Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.29.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). BioCryst Pharmaceuticals had a negative return on equity of 106.53% and a negative net margin of 261.18%. The business had revenue of $3.89 million for the quarter, compared to the consensus estimate of $6.07 million. During the same period in the previous year, the company posted ($0.06) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was down 56.7% compared to the same quarter last year. analysts predict that BioCryst Pharmaceuticals will post -0.79 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/04/17/biocryst-pharmaceuticals-bcrx-receives-daily-news-impact-rating-of-0-03.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.